The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis
Open Access
- 19 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Advances in Rheumatology
- Vol. 61 (1), 1-7
- https://doi.org/10.1186/s42358-021-00171-x
Abstract
To assess the prevalence and clinical relevance of anti-Jo-1 autoantibodies in a representative sample of patients with definite dermatomyositis (DM). This retrospective cohort study took place from 2005 to 2020 and assessed 118 adult patients from a tertiary center who were diagnosed with definite DM. A commercial kit was used to detect anti-Jo-1 autoantibodies. The presence of anti-Jo-1 autoantibodies was observed in 10 out of 118 (8.5%) patients with definite DM. The following variables were comparable between individuals with and without anti-Jo-1 autoantibodies: age at diagnosis, sex, ethnicity, disease duration, follow-up period, recurrence rate, complete clinical response, death rate, and cancer incidence. There was no difference in clinical features between groups, except for an increased prevalence of “mechanic’s hands,” joint involvement, and lung disease, as well as a reduced occurrence of skin findings in patients positive for anti-Jo-1 autoantibodies. No anti-Jo-1-positive patients went into remission; they required greater use of glucocorticoids and immunosuppressive drugs. Anti-Jo-1 positivity was found in 8.5% of patients with definite DM. This autoantibody was associated with an antisynthetase syndrome phenotype and might predict clinical outcomes in patients with definite DM.Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/09079-1)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (303379/2018-9)
- Faculdade de Medicina da USP - SP (.)
This publication has 25 references indexed in Scilit:
- Myositis Specific Autoantibodies: A Clinical PerspectiveOpen Access Rheumatology: Research and Reviews, 2020
- Cluster Analysis Using Anti–Aminoacyl-tRNA Synthetases and SS-A/Ro52 antibodies in Patients With Polymyositis/DermatomyositisJCR: Journal of Clinical Rheumatology, 2018
- Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific AutoantibodiesCurrent Rheumatology Reports, 2018
- 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major SubgroupsArthritis & Rheumatology, 2017
- Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositisRheumatology International, 2016
- Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features—a Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2015
- The clinical phenotype associated with myositis-specific and associated autoantibodies: A meta-analysis revisiting the so-called antisynthetase syndromeAutoimmunity Reviews, 2014
- Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositisClinics, 2013
- Polymyositis and DermatomyositisThe New England Journal of Medicine, 1975
- Polymyositis and DermatomyositisThe New England Journal of Medicine, 1975